Citigroup
AXDX

Citigroup’s Accelerate Diagnostics AXDX Stock Holding History

Citigroup’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-170
Closed -$39K – 7685
2019
Q2 		$39K Sell
170
-880
-84% -$172K ﹤0.01% 6684
2019
Q1 		$221K Sell
1,050
-1,600
-60% -$300K ﹤0.01% 4993
2018
Q4 		$305K Buy
2,650
+2,190
+476% +$324K ﹤0.01% 4611
2018
Q3 		$106K Sell
460
-2,740
-86% -$606K ﹤0.01% 5838
2018
Q2 		$714K Buy
3,200
+2,960
+1,233% +$662K ﹤0.01% 3713
2018
Q1 		$55K Sell
240
-150
-38% -$39.4K ﹤0.01% 6089
2017
Q4 		$102K Sell
390
-80
-17% -$18.8K ﹤0.01% 5622
2017
Q3 		$106K Buy
+470
New +$115K ﹤0.01% 5522

Other funds holding AXDX

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
Lido Advisors
Lido Advisors Los Angeles, California $36.8B AUM 26.6% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CS
Cannell & Spears New York $5.62B AUM 41.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
TWA
TCI Wealth Advisors Tucson, Arizona $2.31B AUM 26.52% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Citigroup's AXDX Position: Q1 2025 in Review

Citigroup sold out of Accelerate Diagnostics (AXDX) in Q1 2025, closing a stake of 10,678 shares — an estimated $12.8K sold.

Citigroup first reported a position in AXDX in Q2 2013 and held it in 38 quarters. The position peaked at $485K in Q4 2016. 43 funds tracked by Wall St. Rank hold AXDX as of Q1 2025.

  • Citigroup reported no remaining Accelerate Diagnostics position as of Q1 2025 after selling out during the quarter.
  • Citigroup sold 10,678 Accelerate Diagnostics shares in Q1 2025, an estimated $12.8K.
  • Citigroup first reported a position in Accelerate Diagnostics in Q2 2013 and held it in 38 quarters.
  • Citigroup's Accelerate Diagnostics position peaked at $485K in Q4 2016.
  • 43 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q1 2025.

Based on Citigroup's 13F filing for Q1 2025, filed 12 May 2025.